MX2019011260A - Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. - Google Patents
Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.Info
- Publication number
- MX2019011260A MX2019011260A MX2019011260A MX2019011260A MX2019011260A MX 2019011260 A MX2019011260 A MX 2019011260A MX 2019011260 A MX2019011260 A MX 2019011260A MX 2019011260 A MX2019011260 A MX 2019011260A MX 2019011260 A MX2019011260 A MX 2019011260A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- taa
- recognizing constructs
- tcr
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/427—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención atañe a constructos reconocedores de antígeno dirigidos contra antígenos asociados a tumores (TAA), en particular contra el antígeno expresado preferencialmente en el melanoma (PRAME, por sus siglas en inglés). La invención proporciona en concreto moléculas basadas en un nuevo receptor de linfocitos T (TCR) que son selectivas y específicas hacia el antígeno de la invención que es expresado por tumores. El TCR de la invención, así como los fragmentos de unión con el TAA que derivan del mismo, están destinados al uso en el diagnóstico, el tratamiento y la prevención de enfermedades tumorales que expresan el TAA. Además, se proporcionan ácidos nucleicos que codifican los constructos reconocedores del antígeno de la invención, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan los constructos reconocedores del antígeno y las composiciones farmacéuticas que comprenden los compuestos de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475329P | 2017-03-23 | 2017-03-23 | |
| DE102017106305.6A DE102017106305A1 (de) | 2017-03-23 | 2017-03-23 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| PCT/EP2018/057482 WO2018172533A2 (en) | 2017-03-23 | 2018-03-23 | T cell receptors and immune therapy using the same against prame positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019011260A true MX2019011260A (es) | 2019-12-05 |
Family
ID=61899213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011260A MX2019011260A (es) | 2017-03-23 | 2018-03-23 | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. |
| MX2023003463A MX2023003463A (es) | 2017-03-23 | 2019-09-20 | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003463A MX2023003463A (es) | 2017-03-23 | 2019-09-20 | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11236145B2 (es) |
| EP (2) | EP4450087A3 (es) |
| JP (2) | JP2020511152A (es) |
| KR (2) | KR20240151870A (es) |
| CN (2) | CN118852404A (es) |
| AU (2) | AU2018240501B2 (es) |
| BR (1) | BR112019019523A2 (es) |
| CA (1) | CA3056493A1 (es) |
| CL (1) | CL2019002645A1 (es) |
| CO (1) | CO2019011688A2 (es) |
| CR (1) | CR20190482A (es) |
| DK (1) | DK3600409T3 (es) |
| ES (1) | ES2986840T3 (es) |
| FI (1) | FI3600409T3 (es) |
| HR (1) | HRP20241228T1 (es) |
| HU (1) | HUE068640T2 (es) |
| IL (2) | IL269578B2 (es) |
| LT (1) | LT3600409T (es) |
| MA (1) | MA47932B1 (es) |
| MD (1) | MD3600409T2 (es) |
| MX (2) | MX2019011260A (es) |
| MY (1) | MY199084A (es) |
| PE (1) | PE20191493A1 (es) |
| PH (1) | PH12019502151A1 (es) |
| PL (1) | PL3600409T3 (es) |
| PT (1) | PT3600409T (es) |
| RS (1) | RS65924B1 (es) |
| SG (1) | SG11201908023YA (es) |
| SI (1) | SI3600409T1 (es) |
| SM (1) | SMT202400351T1 (es) |
| TW (1) | TWI799922B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| KR20230008254A (ko) | 2017-11-08 | 2023-01-13 | 바이오엔테크 유에스 인크. | T 세포 제조 조성물 및 방법 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| WO2020172332A1 (en) | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| BR112021022089A2 (pt) * | 2019-05-08 | 2022-02-08 | Janssen Biotech Inc | Materiais e métodos para modulação da imunidade mediada por células t |
| TWI872076B (zh) | 2019-05-27 | 2025-02-11 | 美商英麥提克斯股份有限公司 | 病毒載體及其在授受性細胞療法之應用 |
| MX2022005922A (es) * | 2019-11-18 | 2022-09-02 | BioNTech SE | Receptores de tcr de prame y usos de estos. |
| KR20220131956A (ko) * | 2020-01-24 | 2022-09-29 | 리제너론 파아마슈티컬스, 인크. | 흑색종에서 우선적으로 발현되는 항원(prame) t 세포 수용체 및 이의 사용 방법 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022017435A1 (zh) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用 |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| MX2023007817A (es) | 2020-12-31 | 2023-09-13 | Immatics Us Inc | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
| IL308257A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Antigen binding proteins that uniquely bind PRAME |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230190805A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of identifying metastatic lesions in a patient and treating thereof |
| CN113789304B (zh) * | 2021-10-14 | 2023-03-31 | 深圳大学总医院 | 高亲和力tcr及其应用 |
| CN113817044B (zh) * | 2021-10-14 | 2023-10-13 | 深圳大学总医院 | T细胞受体、相关工程化细胞及其应用 |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| IL316137A (en) | 2022-04-08 | 2024-12-01 | Regeneron Pharma | Multipartite receptor and signaling complex |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| CA3250304A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | IL-15 Bound to a Membrane, CD8 Polypeptides, Cells, Compositions and Related Methods of Use |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115073584B (zh) * | 2022-05-07 | 2023-10-20 | 溧阳瑅赛生物医药有限公司 | 一种特异性识别prame抗原肽的tcr及其应用 |
| CN117946245B (zh) * | 2023-02-23 | 2024-08-02 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US9803246B2 (en) | 2011-06-28 | 2017-10-31 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific T cell |
| RU2578009C2 (ru) | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| ES2959683T3 (es) | 2014-07-15 | 2024-02-27 | Juno Therapeutics Inc | Células manipuladas para terapia celular adoptiva |
| JP2018510627A (ja) | 2015-03-10 | 2018-04-19 | レイデン ユニバーシティ メディカル センター | メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用 |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| WO2016191246A2 (en) | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
| CN106084036A (zh) | 2015-11-02 | 2016-11-09 | 广州市香雪制药股份有限公司 | 识别prame抗原短肽的t细胞受体 |
| CN106478809B (zh) | 2015-11-06 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的tcr |
| CN106519019B (zh) | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | 识别prame抗原的tcr |
| CN106831978B (zh) | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原的t细胞受体 |
| CN106699874B (zh) | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的t细胞受体 |
| CA3022129A1 (en) | 2016-06-17 | 2017-12-21 | Medigene Immunotherapies Gmbh | T cell receptors and uses thereof |
| DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
-
2018
- 2018-03-22 US US15/928,785 patent/US11236145B2/en active Active
- 2018-03-23 PL PL18715559.3T patent/PL3600409T3/pl unknown
- 2018-03-23 BR BR112019019523-8A patent/BR112019019523A2/pt unknown
- 2018-03-23 IL IL269578A patent/IL269578B2/en unknown
- 2018-03-23 TW TW110126772A patent/TWI799922B/zh active
- 2018-03-23 PT PT187155593T patent/PT3600409T/pt unknown
- 2018-03-23 CA CA3056493A patent/CA3056493A1/en active Pending
- 2018-03-23 SG SG11201908023Y patent/SG11201908023YA/en unknown
- 2018-03-23 FI FIEP18715559.3T patent/FI3600409T3/fi active
- 2018-03-23 MA MA47932A patent/MA47932B1/fr unknown
- 2018-03-23 HU HUE18715559A patent/HUE068640T2/hu unknown
- 2018-03-23 KR KR1020247033132A patent/KR20240151870A/ko active Pending
- 2018-03-23 DK DK18715559.3T patent/DK3600409T3/da active
- 2018-03-23 RS RS20240992A patent/RS65924B1/sr unknown
- 2018-03-23 ES ES18715559T patent/ES2986840T3/es active Active
- 2018-03-23 SM SM20240351T patent/SMT202400351T1/it unknown
- 2018-03-23 KR KR1020197030006A patent/KR20190132655A/ko not_active Ceased
- 2018-03-23 AU AU2018240501A patent/AU2018240501B2/en active Active
- 2018-03-23 JP JP2019552175A patent/JP2020511152A/ja not_active Withdrawn
- 2018-03-23 LT LTEPPCT/EP2018/057482T patent/LT3600409T/lt unknown
- 2018-03-23 HR HRP20241228TT patent/HRP20241228T1/hr unknown
- 2018-03-23 MD MDE20200121T patent/MD3600409T2/ro unknown
- 2018-03-23 CN CN202410804111.1A patent/CN118852404A/zh active Pending
- 2018-03-23 SI SI201831150T patent/SI3600409T1/sl unknown
- 2018-03-23 EP EP24194122.8A patent/EP4450087A3/en active Pending
- 2018-03-23 CR CR20190482A patent/CR20190482A/es unknown
- 2018-03-23 PE PE2019001902A patent/PE20191493A1/es unknown
- 2018-03-23 CN CN201880019206.5A patent/CN110494160B/zh active Active
- 2018-03-23 MX MX2019011260A patent/MX2019011260A/es unknown
- 2018-03-23 MY MYPI2019005257A patent/MY199084A/en unknown
- 2018-03-23 EP EP18715559.3A patent/EP3600409B1/en active Active
-
2019
- 2019-09-16 CL CL2019002645A patent/CL2019002645A1/es unknown
- 2019-09-19 PH PH12019502151A patent/PH12019502151A1/en unknown
- 2019-09-20 MX MX2023003463A patent/MX2023003463A/es unknown
- 2019-10-22 CO CONC2019/0011688A patent/CO2019011688A2/es unknown
-
2021
- 2021-12-16 US US17/553,017 patent/US20220098270A1/en active Pending
-
2023
- 2023-03-20 JP JP2023044130A patent/JP7787119B2/ja active Active
-
2024
- 2024-01-30 IL IL310552A patent/IL310552B1/en unknown
-
2025
- 2025-03-24 AU AU2025202086A patent/AU2025202086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011688A2 (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame | |
| CO2020000357A2 (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
| CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
| MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
| MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
| CL2019000366A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
| EA202190243A1 (ru) | Применение химерных антигенных рецепторов к bcma | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| MX2015015511A (es) | Prediccion de la inmunogenicidad en epitopos de celulas t. | |
| CL2018000422A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
| MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| CL2017002244A1 (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015). | |
| MX2015010836A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado. | |
| MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
| MX360497B (es) | Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos. | |
| MX2017002205A (es) | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. | |
| CR20180074A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| CU24437B1 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
| AR091545A1 (es) | Anticuerpos anti-egfr y usos de los mismos |